undamentalytics Newsletter
Sign in

Standard Biotools Inc. income statement

In fiscal 2025, Standard Biotools Inc. reported revenue of $85.3m, down 6.2% on the year before, operating income of −$110m (a -129.2% margin) and net income of −$74.9m, or −$0.20 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue253443527111611510410211311713813198106918585
Cost of revenue——000000505153——6156464342
Gross profit——43527111611458526264——3750454343
Research and development121314172043393831303236383726292618
Selling, general and administrative202431384871839380808498991028810311087
Operating income−18−15−19−18−19−52−50−73−58−48−52−51−67−116−77−127−110−95
Interest expense3231056661444445———
Income before tax−19−17−22−19−16−58−55−80−64−61−67−54−64−193−74−90−97−91
Income tax−00000−5−1−4−3−2−2−1−4−301−38−37
Net income−19−17−22−19−17−53−53−76−61−59−65−53−59−190−75−139−7585
Diluted EPS−$1.10−$0.89−$1.81−$0.86−$0.65−$1.90−$1.86−$2.62−$1.84−$1.49−$0.97−$0.74−$0.78−$2.43−$0.94−$0.52−$0.20$0.22
Diluted shares (average)—19m18m22m25m28m29m29m33m40m67m72m76m78m79m353m382m387m
EBITDA−16−13−17−16−16−48−45−66−51−43−47−47−64−104−64−115−101−90

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: HBIO vs LABCDXS vs LABBNR vs LAB

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Standard Biotools Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Standard Biotools Inc.